PDF icon Download PDF
Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer 2022; 11(02): 125-132
DOI: 10.1055/s-0042-1742711
Original Article
Genitourinary Cancer

Prognostic Significance of HE4 Tissue Expression in Serous Epithelial Ovarian Carcinoma

Ankita Sethi
1   Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India
,
Lalit Kumar
2   Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Sandeep Mathur
3   Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
,
Reeta Mahey
1   Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India
,
Garima Kachhawa
1   Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India
,
Neerja Bhatla
1   Department of Obstetrics and Gynaecology, All India Institute of Medical Sciences, New Delhi, India
› Author Affiliations
› Further Information
Also available ateRef
  Permissions and Reprints
Preview

Abstract

Zoom
Neerja Bhatla

Background Human Epididymis protein 4 (HE4) is expressed in ovarian cancer. Preoperative serum testing is still not widely available. This pilot study aimed to investigate the magnitude of expression of HE4 in tissue sections of serous epithelial ovarian carcinoma, its correlation with clinical outcome, and the feasibility of HE4 immunohistochemistry as a prognostic marker.

Materials and Method In this ambispective study, immunohistochemistry (IHC) was used to evaluate tissue sections of ovarian serous epithelial carcinoma at primary cytoreductive surgery. On HE4 immunohistochemistry (IHC), the magnitude of HE4 expression was assessed categorically as high or low HE4 expression and semiquantitatively by the H-score, and correlated with clinical outcome in terms of survival status, progression-free survival, and overall survival.

Results Of 32 cases, most (n = 31, 96.8%) were positive for HE4 IHC. The mean age was 49 ± 8.2 years; 29 (90.6%) patients were in FIGO stage IIIC; 25 (78.9%) had ≥1cm residual disease after surgery; 31 (96.8%) received adjuvant chemotherapy, either 3-weekly (n = 25, 81.2%) or dose-dense weekly (n = 6, 18.8%) regimen. The majority (n = 31, 96.8%) had a high-grade tumor, of whom 19 (59.4%) had high HE4 expression and 13(40.6%) patients had H-score in the range of 5 to 8. The mean H-score was 6.97 ± 3.61 (range 0 to 12). The overall survival of the study population at 64 months was 36.65% (95% CI: 8.59–66.34), with median overall survival of 59 months. A new scoring system was developed combining categorical HE4 expression and serum CA-125 levels; the combination of HE4 expression with postoperative CA-125 levels was found to be the best prognostic marker for overall survival (p = 0.05). A composite score of 2 identified patients with poor progression-free survival (HR 4.64, p = 0.039) and overall survival (HR 5.45, p = 0.05).

Conclusion The new composite scoring system using HE4 IHC with postoperative serum CA-125 levels offers an extremely useful option for prognosticating patients with serous epithelial ovarian carcinoma than serum CA-125 alone. This is useful where preoperative records are not available to the treating clinician.

Keywords

CA-125 - HE4 tissue expression - human epididymis protein 4 - immunohistochemistry - prognostic marker - serous epithelial ovarian cancer


Publication History

Article published online:
27 February 2022

© 2022. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India